Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma
出版年份 2014 全文链接
标题
Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma
作者
关键词
-
出版物
BRITISH JOURNAL OF CANCER
Volume 111, Issue 4, Pages 689-695
出版商
Springer Nature
发表日期
2014-06-18
DOI
10.1038/bjc.2014.327
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
- (2013) Allan Lipton et al. BREAST CANCER RESEARCH AND TREATMENT
- Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
- (2013) M Cizkova et al. BRITISH JOURNAL OF CANCER
- SRC Signaling Is Crucial in the Growth of Synovial Sarcoma Cells
- (2013) S. Michels et al. CANCER RESEARCH
- Increased signalling of EGFR and IGF1R and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas
- (2012) A Gallardo et al. BRITISH JOURNAL OF CANCER
- Quantitative Proteomics with siRNA Screening Identifies Novel Mechanisms of Trastuzumab Resistance in HER2 Amplified Breast Cancers
- (2012) Alaina P. Boyer et al. MOLECULAR & CELLULAR PROTEOMICS
- PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab
- (2011) J. D. Jensen et al. ANNALS OF ONCOLOGY
- Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells
- (2011) Jayashree P. Joshi et al. BIOCHEMICAL PHARMACOLOGY
- Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial
- (2011) J. Huober et al. BREAST
- Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions
- (2011) Bolin Liu et al. CELL CYCLE
- Dasatinib: An Anti-Tumour Agent via Src Inhibition
- (2011) Antonio Gnoni et al. CURRENT DRUG TARGETS
- Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
- (2011) Siyuan Zhang et al. NATURE MEDICINE
- PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
- (2011) V Serra et al. ONCOGENE
- Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition
- (2011) B N Rexer et al. ONCOGENE
- PTEN, PIK3CA, p-AKT, and p-p70S6K Status
- (2010) Francisco J. Esteva et al. AMERICAN JOURNAL OF PATHOLOGY
- Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo
- (2010) Yi Chen et al. BREAST CANCER RESEARCH AND TREATMENT
- Recombinant Human Erythropoietin Antagonizes Trastuzumab Treatment of Breast Cancer Cells via Jak2-Mediated Src Activation and PTEN Inactivation
- (2010) Ke Liang et al. CANCER CELL
- Transforming Growth Factor Induces Clustering of HER2 and Integrins by Activating Src-Focal Adhesion Kinase and Receptor Association to the Cytoskeleton
- (2009) S. E. Wang et al. CANCER RESEARCH
- Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas
- (2008) Enrique Lerma et al. VIRCHOWS ARCHIV
- Src family kinases: Regulation of their activities, levels and identification of new pathways
- (2007) Evan Ingley BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now